Reid Hoffman says the next AI gold rush is in drug discovery

In a recent episode of 'The Possible Podcast,' Reid Hoffman, LinkedIn's cofounder, highlighted a burgeoning opportunity in artificial intelligence within the pharmaceutical sector. He emphasized that the current interest in AI technologies should extend into medicine, where substantial revenue prospects await. "Now is the time for medicine," Hoffman stated, pointing out that while many focus on AI advancements like those from OpenAI and Anthropic, the healthcare market presents an even larger potential for financial gain. Hoffman noted that the lengthy timeline for bringing a drug to market, often exceeding a decade, underscores the need for innovation in drug discovery. His company, Manas AI, based in New York, is at the forefront of utilizing AI to streamline this process. The firm aims to enhance early-stage research efficiency before committing significant resources to the development phase. "What we're doing at Manas is creating a drug discovery factory for monopolies because drugs are essentially legal … 20-year-long monopolies," he explained. The patent system grants a 20-year exclusivity period for new drugs from the filing date in the U.S., although this can vary depending on the drug's purpose. For instance, treatments for rare diseases can receive up to seven years of market exclusivity. Since the onset of the COVID-19 pandemic, several AI startups have emerged, striving to minimize the time and costs associated with delivering essential medicines to patients. Hoffman also contested the idea that the pharmaceutical market is a winner-take-all scenario. Drawing comparisons to the market for GLP-1 drugs, he observed that multiple companies can thrive simultaneously, generating tens of billions in revenue. "It's very possible to have a monopoly on your drug while other drugs in the same category can also be extremely lucrative," he remarked. He concluded by urging individuals and businesses to explore the untapped potential of AI in discovering and developing the next wave of medical innovations.